The Costochondritis market is comprehensively segmented to address the varied facets of diagnosis and treatment, offering a granular view of investment opportunities. Key segmentation categories include: Diagnosis (clinical assessment, imaging, lab tests), Treatment Type, and End-User. Within the Treatment Type, the market is sub-segmented into Drugs, Therapy, and Surgery. Drugs, particularly Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), constitute the largest sub-segment due to their role as the first-line treatment for pain and inflammation. The Therapy sub-segment is gaining traction, encompassing physical therapy, heat/cold applications, and manual manipulative techniques. Surgery is the least common, typically reserved for rare, refractory cases involving infectious factors or tumors. By End-User, the market is segmented into Hospitals & Clinics, Diagnostic Centers, Research Centers, and Ambulatory Surgery Centers. Hospitals and clinics hold the majority share as they are the primary points of contact for emergency and initial diagnosis of chest pain. This multifaceted Costochondritis Market segment structure provides essential data for pharmaceutical manufacturers and healthcare service providers to tailor their offerings.